TOKYO (REUTERS) – Japan’s Shionogi & Co said on Wednesday (Sept 29) it plans to make at least 1 million doses of a new antiviral treatment for Covid-19 for domestic use by March 2022.

The company plans to submit the drug, a protease inhibitor known as S-217622, for regulatory approval in Japan by the end of this year, Chief Executive Isao Teshirogi said at a briefing.

Shionogi started Phase II/III trials of the drug in Japan on Monday.

The company is also planning global late-stage trials ahead of filings in the United States and Europe.

The drug can be taken in pill form and is intended for patients in the early stages of Covid-19, compared with antibody treatments that have to be infused by medical staff and are reserved for more serious cases.

More on this topic

Join ST’s Telegram channel here and get the latest breaking news delivered to you.

Source: Read Full Article